XML 32 R22.htm IDEA: XBRL DOCUMENT v3.25.3
Product Sales (Tables)
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Product Sales
Net product sales consist of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In millions)2025202420252024
EYLEA HD®
U.S.$430.6 $392.3 $1,130.6 $896.5 
EYLEA®
U.S.680.6 1,144.6 2,170.9 3,576.7 
Total EYLEA HD and EYLEAU.S.1,111.2 1,536.9 3,301.5 4,473.2 
Libtayo®
U.S.219.1 194.5 659.4 536.1 
Libtayo
Rest of world
146.1 94.1 367.4 313.8 
Total Libtayo
Global
365.2 288.6 1,026.8 849.9 
Praluent®
U.S.67.7 52.9 190.3 179.0 
Evkeeza®
U.S.42.8 32.4 114.9 87.6 
Inmazeb®
U.S.
— 35.6 — 36.6 
Other products
Global
0.8 — 0.8 — 
$1,587.7 $1,946.4 $4,634.3 $5,626.3 
Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows:
Statement of Operations Classification
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In millions)2025202420252024
Regeneron's share of profits
Collaboration revenue$1,455.5 $1,088.3 $3,755.7 $2,880.6 
Reimbursement for manufacturing of commercial suppliesCollaboration revenue$161.5 $175.1 $488.1 $438.2 
Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses
(R&D expense)
$(23.5)$(7.8)$(56.9)$(35.5)
Reimbursement of commercialization-related expenses
Reduction of SG&A expense$182.6 $169.0 $535.8 $459.3 
Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:
Statement of Operations Classification
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In millions)2025202420252024
Regeneron's share of profits
Collaboration revenue$311.9 $367.6 $1,012.6 $1,054.5 
Reimbursement for manufacturing of commercial supplies
Collaboration revenue$32.9 $23.2 $91.1 $67.4 
Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses
(R&D expense)
$(3.9)$(11.8)$(18.9)$(35.2)
Schedules of Sales to Customers as Percentage of Total Gross Product Revenue Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025202420252024
Customer A
49 %51 %51 %51 %
Customer B
30 %24 %26 %24 %